AIM: To detect the expression of DPC4 in malignant and non-malignant specimens of human pancreas, and observe the inhibition of retroviral pLXSN containing DPC4 on pancreatic carcinoma cells in vitro. METHODS: The expression of DPC4 was determined in 40 pancreatic adenocarcinoma and 36 non-malignant pancreatic specimens by reverse-transcriptase polymerase chain reaction (RT-PCR) and immunohisto-chemistry. Furthermore, we constructed retroviral vectors containing DPC4, which then infected the pancreatic carcinoma cell line BxPC-3. Cell growth in vitro after being infected was observed, and the vascular endothelial growth factor (VEGF) mRNA level in the daughter cells was determined by semi-quantitative PCR assay. RESULTS: The RT-PCR assay showed a positive rate of DPC4 mRNA in 100% (36/36) of normal specimens, compared to 40% (16/40) in adenocarcinoma specimens. The regional and intense positive cases of DPC4 expression in adenocarcinoma detected by immunohistochemistry were 10 and four, whereas it was all positive expression in normal tissues. There was a significant difference of DPC4 expression between them. The stable expression of DPC4 in the pancreatic carcinoma cells BxPC-3 could be resumed by retroviral vector pLXSN transfection, and could inhibit cell growth in vitro. Rather, DPC4 could decrease VEGF mRNA transcription levels. CONCLUSION: The deletion of DPC4 expression in pancreatic carcinoma suggests that loss of DPC4 may be involved in the development of pancreatic carcinoma. The retroviral vector pLXSN containing DPC4 can inhibit the proliferation of pancreatic carcinoma cells, and down-regulate the level of VEGF.
AIM: To detect the expression of DPC4 in malignant and non-malignant specimens of human pancreas, and observe the inhibition of retroviral pLXSN containing DPC4 on pancreatic carcinoma cells in vitro. METHODS: The expression of DPC4 was determined in 40 pancreatic adenocarcinoma and 36 non-malignant pancreatic specimens by reverse-transcriptase polymerase chain reaction (RT-PCR) and immunohisto-chemistry. Furthermore, we constructed retroviral vectors containing DPC4, which then infected the pancreatic carcinoma cell line BxPC-3. Cell growth in vitro after being infected was observed, and the vascular endothelial growth factor (VEGF) mRNA level in the daughter cells was determined by semi-quantitative PCR assay. RESULTS: The RT-PCR assay showed a positive rate of DPC4 mRNA in 100% (36/36) of normal specimens, compared to 40% (16/40) in adenocarcinoma specimens. The regional and intense positive cases of DPC4 expression in adenocarcinoma detected by immunohistochemistry were 10 and four, whereas it was all positive expression in normal tissues. There was a significant difference of DPC4 expression between them. The stable expression of DPC4 in the pancreatic carcinoma cells BxPC-3 could be resumed by retroviral vector pLXSN transfection, and could inhibit cell growth in vitro. Rather, DPC4 could decrease VEGF mRNA transcription levels. CONCLUSION: The deletion of DPC4 expression in pancreatic carcinoma suggests that loss of DPC4 may be involved in the development of pancreatic carcinoma. The retroviral vector pLXSN containing DPC4 can inhibit the proliferation of pancreatic carcinoma cells, and down-regulate the level of VEGF.
Authors: M Tascilar; H G Skinner; C Rosty; T Sohn; R E Wilentz; G J Offerhaus; V Adsay; R A Abrams; J L Cameron; S E Kern; C J Yeo; R H Hruban; M Goggins Journal: Clin Cancer Res Date: 2001-12 Impact factor: 12.531
Authors: H Ijichi; T Ikenoue; N Kato; Y Mitsuno; G Togo; J Kato; F Kanai; Y Shiratori; M Omata Journal: Biochem Biophys Res Commun Date: 2001-11-30 Impact factor: 3.575
Authors: P S Moore; B Sipos; S Orlandini; C Sorio; F X Real; N R Lemoine; T Gress; C Bassi; G Klöppel; H Kalthoff; H Ungefroren; M Löhr; A Scarpa Journal: Virchows Arch Date: 2001-12 Impact factor: 4.064
Authors: I Schwarte-Waldhoff; O V Volpert; N P Bouck; B Sipos; S A Hahn; S Klein-Scory; J Lüttges; G Klöppel; U Graeven; C Eilert-Micus; A Hintelmann; W Schmiegel Journal: Proc Natl Acad Sci U S A Date: 2000-08-15 Impact factor: 11.205
Authors: K Woodford-Richens; J Williamson; S Bevan; J Young; B Leggett; I Frayling; Y Thway; S Hodgson; J C Kim; T Iwama; M Novelli; D Sheer; R Poulsom; N Wright; R Houlston; I Tomlinson Journal: Cancer Res Date: 2000-05-01 Impact factor: 12.701
Authors: Juthika Kundu; S M Riajul Wahab; Joydeb Kumar Kundu; Yoon-La Choi; Ozgur Cem Erkin; Hun Seok Lee; Sang Gyu Park; Young Kee Shin Journal: Int J Oncol Date: 2012-06-12 Impact factor: 5.650
Authors: Marie Rouanet; Marine Lebrin; Fabian Gross; Barbara Bournet; Pierre Cordelier; Louis Buscail Journal: Int J Mol Sci Date: 2017-06-08 Impact factor: 5.923